JP2017119628A - 置換アゾール化合物及び糖尿病治療薬 - Google Patents

置換アゾール化合物及び糖尿病治療薬 Download PDF

Info

Publication number
JP2017119628A
JP2017119628A JP2014098007A JP2014098007A JP2017119628A JP 2017119628 A JP2017119628 A JP 2017119628A JP 2014098007 A JP2014098007 A JP 2014098007A JP 2014098007 A JP2014098007 A JP 2014098007A JP 2017119628 A JP2017119628 A JP 2017119628A
Authority
JP
Japan
Prior art keywords
group
ring
compound
formula
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014098007A
Other languages
English (en)
Japanese (ja)
Inventor
友輔 新谷
Yusuke Shintani
友輔 新谷
雅俊 丹羽
Masatoshi Niwa
雅俊 丹羽
壮一 門馬
Soichi Momma
壮一 門馬
聖志 石山
Kiyoshi Ishiyama
聖志 石山
幸宏 繁田
Yukihiro Shigeta
幸宏 繁田
嘉伸 嶋澤
Yoshinobu Shimazawa
嘉伸 嶋澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Priority to JP2014098007A priority Critical patent/JP2017119628A/ja
Priority to PCT/JP2015/063525 priority patent/WO2015170775A1/fr
Priority to TW104115166A priority patent/TW201625545A/zh
Publication of JP2017119628A publication Critical patent/JP2017119628A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
JP2014098007A 2014-05-09 2014-05-09 置換アゾール化合物及び糖尿病治療薬 Pending JP2017119628A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2014098007A JP2017119628A (ja) 2014-05-09 2014-05-09 置換アゾール化合物及び糖尿病治療薬
PCT/JP2015/063525 WO2015170775A1 (fr) 2014-05-09 2015-05-11 Composé azole substitué et agent thérapeutique pour le diabète
TW104115166A TW201625545A (zh) 2014-05-09 2015-05-11 取代唑化合物及糖尿病治療藥

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014098007A JP2017119628A (ja) 2014-05-09 2014-05-09 置換アゾール化合物及び糖尿病治療薬

Publications (1)

Publication Number Publication Date
JP2017119628A true JP2017119628A (ja) 2017-07-06

Family

ID=54392622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014098007A Pending JP2017119628A (ja) 2014-05-09 2014-05-09 置換アゾール化合物及び糖尿病治療薬

Country Status (3)

Country Link
JP (1) JP2017119628A (fr)
TW (1) TW201625545A (fr)
WO (1) WO2015170775A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397311A (zh) * 2016-08-31 2017-02-15 安徽省鸿鑫生物科技有限公司 一种1‑[5‑(苯基甲氧基)‑2‑吡啶]‑乙酮的制备方法
WO2019068613A1 (fr) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh Nouveaux composés de [1,6]naphthyridine et dérivés utilisés en tant qu'inhibiteurs de cdk8/cdk19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374860A1 (en) * 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
KR20100033419A (ko) * 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
BRPI0909469A2 (pt) * 2008-03-31 2015-12-29 Metabolex Inc compostos de oximetileno de arila e usos dos mesmos
GEP20135907B (en) * 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
AU2010279964B2 (en) * 2009-08-05 2016-02-11 Daiichi Sankyo Company, Limited Amide derivative
SI2628733T1 (sl) * 2010-10-14 2015-10-30 Daiichi Sankyo Company, Limited Derivati acilbenzena
BR112013011865A2 (pt) * 2010-11-23 2016-08-23 Pfizer moduladores de gpr119
JP5973440B2 (ja) * 2011-07-29 2016-08-23 第一三共株式会社 Ｎ−ヘテロ環置換アミド誘導体
MX2014008790A (es) * 2012-01-18 2014-10-13 Daiichi Sankyo Co Ltd Derivado de fenilazol sustituido.

Also Published As

Publication number Publication date
TW201625545A (zh) 2016-07-16
WO2015170775A1 (fr) 2015-11-12

Similar Documents

Publication Publication Date Title
JP6528957B2 (ja) Ｔｒｋ阻害化合物
AU2017200493B2 (en) Heterocyclyl compounds as MEK inhibitors
US9242977B2 (en) Trk-inhibiting compound
US9133122B2 (en) Amide compounds, compositions and uses thereof
US8946439B2 (en) Amide compounds, compositions and uses thereof
AU2015369712B2 (en) Mutant IDH1 inhibitors useful for treating cancer
CN111526877B (zh) 用于ire1抑制的化合物和组合物
JP2022527590A (ja) モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害剤としての複素環式化合物
TW200538098A (en) Therapeutic agents
WO2015089137A1 (fr) Acylguanidines comme inhibiteurs de la tryptophan hydroxylase
JP2014159376A (ja) アザスピロアルカン化合物
WO2015012400A1 (fr) Inhibiteur du transporteur de la glycine
KR20210022646A (ko) 시아노트리아졸 화합물 및 이의 용도
JP2017119628A (ja) 置換アゾール化合物及び糖尿病治療薬
CA3144891A1 (fr) Modulateurs du recepteur alpha des oestrogenes (err.alpha.)
WO2015093534A1 (fr) Composé de triazinone substitué et inhibiteur de canal calcique de type t
WO2015128698A1 (fr) Dérivés d'amine hétérocycliques substitués comme inhibiteurs de multikinase pour le traitement du cancer
JP2014214124A (ja) イミダゾイミダゾロン誘導体
WO2013062074A1 (fr) Dérivé d'imidazolone
Nguyen Synthetic routes to N-heterocycles and the development of small-molecule therapies for cystic fibrosis
JP2017525770A (ja) Ｍａｐｋ阻害剤